Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Open Access
- 1 October 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 5 (10) , 871-884
Abstract
The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients who fail to respond to first-line chemotherapy has sparked interest in immunotherapeutic approaches. However, trials utilizing checkpoint inhibitors targeting the PD-1/PD-L1 axis in TNBC have had underwhelming responses. Here, we investigated the interplay between type I IFN signaling and the PD-1/PD-L1 axis and tested the impact of combining IFN inducers, as immune activators, with anti–PD-1, to induce an antimetastatic immune response. Using models of TNBC, we demonstrated an interplay between type I IFN signaling and tumor cell PD-L1 expression that affected therapeutic response. The data revealed that the type I IFN-inducer poly(I:C) was an effective immune activator and antimetastatic agent, functioning better than anti–PD-1, which was ineffective as a single agent. Poly(I:C) treatment induced PD-L1 expression on TNBC cells, and combined poly(I:C) and anti–PD-1 treatment prolonged metastasis-free survival in a neoadjuvant setting via the induction of a tumor-specific T-cell response. Use of this combination in a late treatment setting did not impact metastasis-free survival, indicating that timing was critical for immunotherapeutic benefit. Together, these data demonstrated anti–PD-1 as an ineffective single agent in preclinical models of TNBC. However, type I IFN inducers were effective immune activators, and neoadjuvant trials combining them with anti–PD-1 to induce a sustained antitumor immune response are warranted. Cancer Immunol Res; 5(10); 871–84. ©2017 AACR.Keywords
All Related Versions
Funding Information
- National Health and Medical Research Council (APP1047747)
- Cancer Council Victoria (APP1127757)
This publication has 51 references indexed in Scilit:
- Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert reviewCritical Reviews in Oncology/Hematology, 2013
- Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapyJournal for ImmunoTherapy of Cancer, 2013
- Strategies for the discovery and development of therapies for metastatic breast cancerNature Reviews Drug Discovery, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- CD11b and CD27 reflect distinct population and functional specialization in human natural killer cellsImmunology, 2011
- Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)FEBS Letters, 2006
- A critical function for type I interferons in cancer immunoeditingNature Immunology, 2005
- Similarities and differences in CD4+ and CD8+ effector and memory T cell generationNature Immunology, 2003
- Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.Journal of Experimental Medicine, 1993
- Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial.BMJ, 1984